Skip to content
2000
Volume 29, Issue 16
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Rifamycins are considered a milestone for tuberculosis (TB) treatment because of their proficient sterilizing ability. Currently, available TB treatments are complicated and need a long duration, which ultimately leads to failure of patient compliance. Some new rifamycin derivatives, i.e., rifametane, TNP-2092 (rifamycin-quinolizinonehybrid), and TNP-2198 (rifamycin-nitromidazole hybrid) are under clinical trials, which are attempting to overcome the problems associated with TB treatment. The undertaken review is intended to compare the pharmacokinetics, pharmacodynamics and safety profiles of these rifamycins, including rifalazil, another derivative terminated in phase II trials, and already approved rifamycins. The emerging resistance of microbes is an imperative consideration associated with antibiotics. Resistance development potential of microbial strains against rifamycins and an overview of chemistry, as well as structure-activity relationship (SAR) of rifamycins, are briefly described. Moreover, issues associated with rifamycins are discussed as well. We expect that newly emerging rifamycins shall appear as potential tools for TB treatment in the near future.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867328666210806114949
2022-05-01
2025-07-13
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867328666210806114949
Loading

  • Article Type:
    Review Article
Keyword(s): ansamycins; rifalazil; rifametane; Rifamycins; TNP-2092; TNP-2198
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test